+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Osimertinib Mesylate Tablets Market by Manufacturer Type (Branded, Generic), End User (Ambulatory Care Center, Hospital, Specialty Clinic), Dosage Strength, Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Osimertinib Mesylate Tablets Market by Manufacturer Type (Branded, Generic), End User (Ambulatory Care Center, Hospital, Specialty Clinic), Dosage Strength, Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Osimertinib Mesylate Tablets Market by Manufacturer Type (Branded, Generic), End User (Ambulatory Care Center, Hospital, Specialty Clinic), Dosage Strength, Indication, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6135129
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Osimertinib mesylate tablets represent a transformative force in the precision oncology landscape, shaping standards of care for patients with EGFR-mutated non-small-cell lung cancer. As adoption accelerates amid evolving regulatory, scientific, and payer environments, informed strategic decisions will be essential for organizations aiming to capture emerging opportunities in this dynamic segment.

Market Snapshot: Growth Opportunities in Osimertinib Mesylate Tablets

The global market for osimertinib mesylate tablets is experiencing steady expansion, driven by advances in molecular oncology, increasing integration of precision medicine, and alignment among regulators, payers, and manufacturers on value-based approaches. Widespread clinical acceptance of third-generation EGFR inhibitors and initiatives supporting genomic testing contribute to a robust compound annual growth rate (CAGR) and rising revenue forecasts. The United States leads in innovation and reimbursement complexity, while regional dynamics in Latin America, EMEA, and Asia-Pacific reflect varying access pathways, local manufacturing capacity, and adoption of generic alternatives.

Scope & Segmentation of the Osimertinib Mesylate Tablet Market

This analysis delivers a comprehensive overview of aftermarket and production trends, highlighting the following market segments and regional coverage:

  • Manufacturer Type: Branded, Generic
  • End User: Ambulatory Care Center, Hospital, Specialty Clinic
  • Dosage Strength: 40 Mg, 80 Mg
  • Indication: First Line Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer (including EGFR Sensitizing Mutation and EGFR T790M Positive), Second Line Non-Small-Cell Lung Cancer
  • Distribution Channel: Hospital Pharmacy (Inpatient Pharmacy, Outpatient Pharmacy), Online Pharmacy (Hybrid, Pure Play), Retail Pharmacy (Chain Pharmacy, Independent Pharmacy)
  • Regional Coverage: Americas (United States – California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Players: AstraZeneca PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Lupin Ltd, Hetero Labs Limited, Zydus Cadila Healthcare Ltd, Cipla Ltd, Natco Pharma Ltd, Aurobindo Pharma Limited

Key Takeaways: Strategic Insights for Senior Decision-Makers

  • Widespread adoption of osimertinib mesylate tablets is being driven by clinical milestones in precision oncology and the rapid evolution of genomic testing infrastructure, positioning targeted therapies at the forefront of NSCLC treatment strategies.
  • Collaboration among pharmaceutical partners, healthcare providers, and patient advocacy groups is optimizing treatment pathways and broadening access, anchored by the effective use of real-world evidence and multidisciplinary care models.
  • Lifecycle management is increasingly critical for branded manufacturers as generic and biosimilar entrants expand, prompting investment in label expansions, combination regimens, and differentiated service offerings to sustain clinical and commercial differentiation.
  • Value-based reimbursement models and performance-linked contracts are reshaping market access, incentivizing robust documentation of therapeutic outcomes and long-term patient benefits.
  • Manufacturers are emphasizing digital health integration, enabling remote patient monitoring, adherence tracking, and enhanced safety reporting, which helps drive personalization and optimize overall patient outcomes.

Tariff Impact: Navigating Cost and Supply Chain Dynamics

Recent changes to United States tariffs on active pharmaceutical ingredients and finished forms have led to new complexities in the global supply chain. Manufacturers are pursuing dual-sourcing, near-shoring, and value engineering to mitigate increased costs and reduce disruption risks. Distribution partners are reevaluating cost-sharing and rebate frameworks, while digital supply chain platforms enhance transparency and forecasting. These shifts underscore the value of agile sourcing and collaborative cross-functional planning for reliable market access.

Methodology & Data Sources

This report integrates secondary research from scientific literature, clinical trials, regulatory databases, and proprietary industry sources, complemented by primary interviews with industry experts, clinicians, payers, and supply chain leaders. Quantitative and qualitative data are triangulated through advanced analytical frameworks and validated via advisory panels to ensure consistency and actionable insights.

Why This Report Matters

  • Enable informed decision-making by providing an end-to-end analysis of market drivers, regulatory trends, and strategic responses relevant to the osimertinib mesylate tablet landscape.
  • Support dynamic portfolio and supply chain strategies, helping organizations anticipate growth opportunities and manage operational challenges, including tariff-related disruptions.
  • Leverage detailed segmentation and actionable recommendations to optimize go-to-market strategies and maintain competitive agility across stakeholder groups.

Conclusion

As the market for osimertinib mesylate tablets advances, responsive strategies integrating clinical evidence, value-based access, and operational resilience will be vital. Senior decision-makers can leverage the insights provided to guide future investments, strengthen positioning, and drive impactful outcomes in precision oncology.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of liquid biopsy testing to guide osimertinib therapy selection and monitor treatment response
5.2. Rising prevalence of EGFR mutation detection leading to earlier osimertinib treatment initiation in NSCLC patients
5.3. Expansion of generic osimertinib mesylate tablet approvals driving price competition and accessibility
5.4. Growing clinical evidence supporting first-line use of osimertinib for central nervous system metastases control in lung cancer
5.5. Strategic partnerships between biotech firms and academic centers accelerating novel combination trials involving osimertinib
5.6. Implementation of patient assistance programs to improve adherence and affordability of osimertinib therapy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Osimertinib Mesylate Tablets Market, by Manufacturer Type
8.1. Introduction
8.2. Branded
8.3. Generic
9. Osimertinib Mesylate Tablets Market, by End User
9.1. Introduction
9.2. Ambulatory Care Center
9.3. Hospital
9.4. Specialty Clinic
10. Osimertinib Mesylate Tablets Market, by Dosage Strength
10.1. Introduction
10.2. 40 Mg
10.3. 80 Mg
11. Osimertinib Mesylate Tablets Market, by Indication
11.1. Introduction
11.2. First Line Non-Small-Cell Lung Cancer
11.3. Metastatic Non-Small-Cell Lung Cancer
11.3.1. Egfr Sensitizing Mutation
11.3.2. Egfr T790M Positive
11.4. Second Line Non-Small-Cell Lung Cancer
12. Osimertinib Mesylate Tablets Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.2.1. Inpatient Pharmacy
12.2.2. Outpatient Pharmacy
12.3. Online Pharmacy
12.3.1. Hybrid
12.3.2. Pure Play
12.4. Retail Pharmacy
12.4.1. Chain Pharmacy
12.4.2. Independent Pharmacy
13. Americas Osimertinib Mesylate Tablets Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Osimertinib Mesylate Tablets Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Osimertinib Mesylate Tablets Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca PLC
16.3.2. Viatris Inc.
16.3.3. Teva Pharmaceutical Industries Ltd
16.3.4. Dr. Reddy’s Laboratories Ltd
16.3.5. Lupin Ltd
16.3.6. Hetero Labs Limited
16.3.7. Zydus Cadila Healthcare Ltd
16.3.8. Cipla Ltd
16.3.9. Natco Pharma Ltd
16.3.10. Aurobindo Pharma Limited
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. OSIMERTINIB MESYLATE TABLETS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. OSIMERTINIB MESYLATE TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. OSIMERTINIB MESYLATE TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. OSIMERTINIB MESYLATE TABLETS MARKET: RESEARCHAI
FIGURE 26. OSIMERTINIB MESYLATE TABLETS MARKET: RESEARCHSTATISTICS
FIGURE 27. OSIMERTINIB MESYLATE TABLETS MARKET: RESEARCHCONTACTS
FIGURE 28. OSIMERTINIB MESYLATE TABLETS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. OSIMERTINIB MESYLATE TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY 40 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY 40 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY 80 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY 80 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY FIRST LINE NON-SMALL-CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY FIRST LINE NON-SMALL-CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY EGFR SENSITIZING MUTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY EGFR SENSITIZING MUTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY EGFR T790M POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY EGFR T790M POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY SECOND LINE NON-SMALL-CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY SECOND LINE NON-SMALL-CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HYBRID, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HYBRID, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY PURE PLAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY PURE PLAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 109. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 114. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 115. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 118. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 119. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 122. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 123. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 124. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 125. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 126. CANADA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 127. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 132. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 133. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 136. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 140. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 141. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 142. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 143. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 144. MEXICO OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 220. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 224. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 225. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 228. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 229. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 232. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 233. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 234. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 235. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 236. GERMANY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 237. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 238. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 239. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 242. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 243. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 246. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 247. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 250. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 251. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 252. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 253. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 254. FRANCE OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 273. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 274. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 275. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 282. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 283. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 286. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 287. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 288. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 289. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 290. ITALY OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 291. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2024 (USD MILLION)
TABLE 292. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025-2030 (USD MILLION)
TABLE 293. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 296. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 297. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 298. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 299. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 300. SPAIN OSIMERTINIB MESYLATE TABLETS MARKET SIZE, BY METASTATIC NON-SMALL-CELL LUNG CANCER, 2025-2030 (USD MILLION)
TAB

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Osimertinib Mesylate Tablets Market report include:
  • AstraZeneca PLC
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Lupin Ltd
  • Hetero Labs Limited
  • Zydus Cadila Healthcare Ltd
  • Cipla Ltd
  • Natco Pharma Ltd
  • Aurobindo Pharma Limited

Related Topics

Related Reports

Doxazosin Mesylate Tablets Market by Indication (Benign Prostatic Hyperplasia, Hypertension), Product Type (Branded, Generic), Dosage Strength, Form Type, End User - Global Forecast 2025-2030 - Product Image

Doxazosin Mesylate Tablets Market by Indication (Benign Prostatic Hyperplasia, Hypertension), Product Type (Branded, Generic), Dosage Strength, Form Type, End User - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Doxazosin Mesylate Extended Release Tablets Market by Indication (Benign Prostatic Hyperplasia, Hypertension), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Strength, End User, Patient Age Group, Payment Type - Global Forecast 2025-2030 - Product Image

Doxazosin Mesylate Extended Release Tablets Market by Indication (Benign Prostatic Hyperplasia, Hypertension), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Strength, End User, Patient Age Group, Payment Type - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Nimesulide Dispersible Tablet Global Market Report 2025 - Product Image

Nimesulide Dispersible Tablet Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Isosorbide Mononitrate Tablet Global Market Report 2025 - Product Image

Isosorbide Mononitrate Tablet Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Imipramine Hydrochloride Tablet Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

Imipramine Hydrochloride Tablet Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 74 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.